Seen And Heard At BIO – From The IN VIVO Blog
Executive Summary
ATLANTA - Throughout the Biotechnology Industry Organization's May 18-21 annual meeting, editors from 1The IN VIVO blog reported on what was the talk of the conference, both in the official sessions and out in the hallways. Here's a roundup of what they found:
You may also be interested in...
Sanofi-Aventis' New R&D Model Aims To Build A Network For Innovation
Sanofi-Aventis' revised R&D structure will include the push down to smaller, more independent structures that has characterized other big pharma companies' efforts to improve their R&D activity
Sanofi-Aventis' New R&D Model Aims To Build A Network For Innovation
Sanofi-Aventis' revised R&D structure will include the push down to smaller, more independent structures that has characterized other big pharma companies' efforts to improve their R&D activity
Sanofi-Aventis' New R&D Model Aims To Build A Network For Innovation
Anticipated reorganization seems to mimic previous actions by Big Pharma, with an emphasis on external collaboration and a move to smaller, independent groups..